The GLP-1 market is projected to face intense competition from both generics (like statins) and high-rebate branded drugs (like ED medications). This dual pressure will squeeze profit margins, drive net prices down significantly, and ultimately compel broad payer coverage due to the drugs' strong clinical return on investment.

The GLP-1 drug revolution is moving beyond weekly injections for wealthy markets. Upcoming pill-form versions will eliminate the need for refrigerated supply chains, opening up distribution in developing countries. Combined with expiring patents, this focus on form factor and cost will enable mass global adoption.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

Despite numerous announcements of new US pharmaceutical factories, tangible production capacity is not immediate. Building a highly automated facility, procuring machinery, and integrating it takes 18-24 months alone. A realistic timeline for significant output from these new investments is three to five years.

The US healthcare system is creating a major bottleneck for GLP-1s. While Medicare is beginning to cover the drugs for seniors, private insurers, who cover two-thirds of Americans, are simultaneously increasing hurdles and dropping coverage, effectively hitting the gas and brakes on a major public health tool.

In the US, if a patented drug is in short supply, compounding pharmacies can legally produce and sell it. Entrepreneurs capitalized on this during GLP-1 shortages by buying raw API from China, creating their own versions, and generating billions in high-margin revenue—a risk large pharma companies avoid due to litigation fears.

For its oral obesity drug Foundeo, Eli Lilly gained approval for a 17mg tablet, despite pivotal trials using a 35mg capsule. The company used a bioequivalence study to justify the switch, a strategic move that halves the amount of active ingredient needed, preemptively addressing massive supply chain challenges.

The introduction of low-cost generic semaglutide in India revealed massive pent-up demand. Volumes surged sixfold in just two months, driving such significant market expansion that the total market value is projected to grow eightfold by 2030, even with lower per-unit prices.

Despite the arrival of low-cost generic semaglutide, superior drugs like Tirzepatide, which offers better efficacy and tolerability, can command premium prices. This creates a durable, high-value market segment that coexists with, rather than being eroded by, cheaper alternatives.